Literature DB >> 3011820

Amplification and overexpression of the EGF receptor gene in primary human glioblastomas.

T A Libermann, H R Nusbaum, N Razon, R Kris, I Lax, H Soreq, N Whittle, M D Waterfield, A Ullrich, J Schlessinger.   

Abstract

The expression of epidermal growth factor (EGF) receptor in brain tumours of glial origin was studied at the protein, mRNA and genomic levels. Four out of 10 glioblastomas that overexpress EGF receptor also have gene amplification. The amplified genes appear to be rearranged, generating an aberrant mRNA in at least one of these tumours. Such receptor defects may be relevant to tumorigenesis of human glioblastomas.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3011820     DOI： 10.1242/jcs.1985.supplement_3.16

Source DB:  PubMed          Journal:  J Cell Sci Suppl        ISSN： 0269-3518


  32 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression.

Authors:  M E Berens; M D Rief; J R Shapiro; D Haskett; A Giese; A Joy; S W Coons
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

3.  Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.

Authors:  Toshiyuki Murai; Takayuki Miyauchi; Toshio Yanagida; Yasushi Sako
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 4.  Mammary gland macrophages: pleiotropic functions in mammary development.

Authors:  Kathryn L Schwertfeger; Jeffrey M Rosen; Donald A Cohen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

Review 5.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Authors:  Toni M Brand; Emily F Dunn; Mari Iida; Rebecca A Myers; Kellie T Kostopoulos; Chunrong Li; Chimera R Peet; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-09-01       Impact factor: 4.742

7.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

Review 8.  Notch signaling in glioblastoma: a developmental drug target?

Authors:  Maria Maddalena Lino; Adrian Merlo; Jean-Louis Boulay
Journal:  BMC Med       Date:  2010-11-15       Impact factor: 8.775

9.  Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs).

Authors:  E M Hiesiger; R L Hayes; D M Pierz; G N Budzilovich
Journal:  J Neurooncol       Date:  1993-05       Impact factor: 4.130

Review 10.  The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective.

Authors:  James T Rutka; Paul Kongkham; Paul Northcott; Carlos Carlotti; Mustafa Guduk; Hirokatsu Osawa; Orlando Moreno; Ho Jun Seol; Andres Restrepo; Adrienne Weeks; Shoichi Nagai; Christian Smith
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.